can i switch from mounjaro to semaglutide Switching Wegovy Guide to switching from Wegovy

Adult people (18 years) with a diagnosis of obesity (body mass index30 kg/m2) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users

You can read the full paper in Nature here: #Genetics #PrecisionMedicine #GLP1 #Obesity #Biotech #Semaglutide #Tirzepatide #Nature #23andMe #GWAS #ClinicalResearch | 24 comments on LinkedIn

Semaglutide significantly improved maximal walking distance in people with symptomatic peripheral arterial disease (PAD) and type 2 diabetes in a trial designed to evaluate the use of a GLP-1 agonist to manage PAD

Semaglutide is a medication gaining popularity for its potential to help individuals achieve significant weight loss

With growing recognition of obesity as a ...